Melanoma UK appoints Rachel Wallace as new Chief Executive Officer.
Melanoma UK appoints Rachel Wallace as new Chief Executive Officer. Melanoma UK has appointed Rachel Wallace as its new Chief Executive Officer, bringing extensive senior leadership experience across the NHS,
Funding Research at Kings College London
Ground breaking research at King’s On Wednesday 7th October Colin (our C.O.O.) visited King’s College London Labs at Guy’s Hospital to present our grant certificate to Professor Sophia Karagiannis. “It
Luke’s going down under to bite against cancer
Facing fears and fighting cancer with a Great White Shark challenge. After facing two cancer diagnoses, Luke Rogers from Staffordshire is turning a lifelong dream into an extraordinary fundraising challenge
Ryan completes Robin Hood Half Marathon
A huge thank you to Ryan Mcevoy who ran the Robin Hood Half Marathon on Sunday 27th September, raising vital funds for Melanoma UK following his wife’s melanoma diagnosis earlier
New National Cancer Board launched
The Department of Health and Social Care (DHSC) has announced the launch of a reformed National Cancer Board, which will scrutinise progress against the Government’s National Cancer Plan.The Board heldMelanoma UK announces Rachel Wallace as new Chief Executive
Melanoma UK announces Rachel Wallace as new Chief Executive Melanoma UK is delighted to announce the appointment of Rachel Wallace as its new Chief Executive Officer, following two years of
Merck & Moderna announce encouraging trial results
A personalised cancer treatment developed by Moderna and Merck has shown positive trial results in helping prevent high-risk melanoma from returning after surgery. A press release from Moderna and Merck
Our 2026 Research Grants Announced
Melanoma UK continues to support leading research projects. Our charity is delighted to announce two winners of our 2026 Grants Call. Following numerous strong applications from all across the UK
CRUK’s National Medical Trial looking to increase recruitment
‘DETERMINE’ is Cancer Research UK’s national precision medicine trial for patients with rare and less common cancers. This trial is looking at matching targeted treatment to people who have